- AU$195.66m
- AU$230.01m
- $71.61m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.97 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -59.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 29.23 | 34.42 | 50.14 | 64.25 | 71.61 | 82.2 | 101.75 | 38.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Its technologies address critical healing needs arising from burns, traumatic injuries, and surgical repairs, through a portfolio and complementary products that support wound bed preparation, definitive closure, and recovery. Its portfolio includes RECELL and two complementary wound care products, PermeaDerm and Cohealyx. Its RECELL technology platform is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient's own skin cells, called Spray-On Skin, at the point of care. Its PermeaDerm is a biosynthetic wound matrix that manufactures, markets, and distributes in the United States, under multi-year agreements with Stedical.
Directors
- Lou Panaccio NEC (64)
- Michael Perry CEO (61)
- Michael Holder CFO (59)
- Kathy McGee COO (56)
- Andrew Quick CTO (50)
- Donna Shiroma GCN (58)
- Erin Liberto OTH (47)
- Jeremy Cook NID (71)
- James Corbett NID (63)
- Suzanne Crowe NID (69)
- Louis Drapeau NID (77)
- Jan Reed NID (61)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- April 17th, 2020
- Public Since
- March 18th, 2012
- No. of Shareholders
- 18,051
- No. of Employees
- 226
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 30,776,689
- Address
- 28159 Avenue Stanford, Suite 220, VALENCIA, 91355
- Web
- https://www.avitamedical.com/
- Phone
- +1 3023513367
- Contact
- Jessica Ekeberg
- Auditors
- Grant Thornton LLP
Upcoming Events for AVH
Similar to AVH
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:28 UTC, shares in AVITA Medical are trading at AU$1.18. This share price information is delayed by 15 minutes.
Shares in AVITA Medical last closed at AU$1.18 and the price had moved by -44.08% over the past 365 days. In terms of relative price strength the AVITA Medical share price has underperformed the ASX All Ordinaries Index by -46.22% over the past year.
The overall consensus recommendation for AVITA Medical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAVITA Medical does not currently pay a dividend.
AVITA Medical does not currently pay a dividend.
AVITA Medical does not currently pay a dividend.
To buy shares in AVITA Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$1.18, shares in AVITA Medical had a market capitalisation of AU$195.66m.
Here are the trading details for AVITA Medical:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AVH
Based on an overall assessment of its quality, value and momentum AVITA Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AVITA Medical is AU$1.27. That is 7.99% above the last closing price of AU$1.18.
Analysts covering AVITA Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.93 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AVITA Medical. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +7.33%.
As of the last closing price of AU$1.18, shares in AVITA Medical were trading -8.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AVITA Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$1.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AVITA Medical's management team is headed by:
- Lou Panaccio - NEC
- Michael Perry - CEO
- Michael Holder - CFO
- Kathy McGee - COO
- Andrew Quick - CTO
- Donna Shiroma - GCN
- Erin Liberto - OTH
- Jeremy Cook - NID
- James Corbett - NID
- Suzanne Crowe - NID
- Louis Drapeau - NID
- Jan Reed - NID